Blue Flower

Dear Madam, Dear Sir

On behalf of the entire NOXXON team I am pleased to welcome you to this section of our website. Now quoted on Euronext Growth - Paris, formerly Alternext, NOXXON is a European biopharmaceutical company developing anticancer treatments targeting the tumor microenvironment.

Our goal is to significantly improve cancer therapies, in particular immuno-oncology approaches, such as checkpoint inhibitors, but also standard therapies such as chemo- and radio-therapy. Patient recruitment has recently passed the 50% mark in the ongoing Phase 1/2 trial of our lead product, NOX-A12, in combination with the immunotherapy agent from Merck & Co./MSD in patients with metastatic colorectal (10 patients) or metastatic pancreatic cancer (10 patients) at the National Center for Tumor diseases in Heidelberg, Germany.

Initial analysis of data from this trial confirms the previously reported and published safety and tolerance profile of NOX-A12, with no serious adverse events related to treatment with NOX-A12 monotherapy. In addition, data from the first four patients suggest that NOX-A12 is able to penetrate tumor tissue and neutralize its target. We are encouraged by the feedback from the clinicians who are very committed to this study and we are working diligently to ensure that we will be able to report top-line data from the entire group of patients in 2018.

We are pleased to count you amongst our shareholders at this crucial phase in our development at a company as we look to increase the therapeutic impact of immunotherapy agents by combining them with NOX-A12 and work to advance our other clinical stage agent further in development.

Best regards

Aram Mangasarian, PhD
Chief Executive Officer
NOXXON

Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017